Bride asked pharmacist to help jump vaccine queue so she could have honeymoon

Family of cop arrested on suspicion of murdering Sarah Everard break silence

Donald Trump issues petty statement as Joe Biden announces vaccination surge

Watch ECB President Lagarde speak after the central bank's latest policy decision

[The stream is slated to start at 8:30 a.m. ET. Please refresh the page if you do not see a player above at that time.]

European Central Bank President Christine Lagarde is speaking at a press conference following the institution's latest monetary policy decision.

The ECB said in a statement earlier that it expects to increase its bond purchases "significantly" next quarter, after bond yields rose in the region.

Subscribe to CNBC on YouTube. 

Boy, 7, with autism makes his first friend – a kind girl with Down's syndrome

Lottery winner spared jail after killing pensioner when he took eyes off road

Aveo extends gains to 106% after drug maker wins FDA approval for kidney cancer treatment

• Aveo shares rose 17% Thursday morning, pointing to a second day of strong gains. 
•  The stock climbed 89% in the previous session after the FDA approval its renal cancer treatment. 
• Aveo plans to make its Fotivda treatment available to US patients at the end of March. 
• See more stories on Insider’s business page.

Shares of Aveo climbed 17% early Thursday, stretching their run higher after the company won US regulatory approval for its renal cancer treatment Fotivda. The stock on Wednesday soared 89% and was subject to two trading halts. Shares closed at $15.28. 

The two-day move higher came after the Food and Drug Administration on Wednesday approved the company’s Fotivda treatment for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies.

With the treatment approval, “Aveo begins its journey as a commercial-stage company,” said Michael Bailey, CEO of Aveo, in a statement.

The company plans to make Fotivda available to patients in the US by March 31.

'Killer cop' Derek Chauvin hit with extra murder charge over George Floyd death

Hunt for man who 'spied on women in their bathrooms for months'

Abducted girl who vanished in 2019 sends secret message begging for help

Mother, 39, with no health issues dies days after second Moderna Covid vaccine

Boy, 14, and woman, 34, die in hospital five days after east London flat fire

Stock Alert: Franco-Nevada Shares Up 2%

Shares of Franco-Nevada Corp. (FNV) are currently trading at $115.94, up $2.90 or 2.57%, with trading volume rising over 286K versus an average volume of 719K shares. The stock has been trading in the range of $77.18 – $166.11 for the past one year.

The company reported Q4 net income of $176.7 million compared to $113.3 million last year. Adjusted net income was $163.0 million or $0.85 per share, higher than the previous year’s $110.8 million or $0.59 per share. Revenue for the quarter soared to $1.02 billion from $844.1 million generated a year ago.

Roblox, Coupang top stock news: LIVE updates

Big Tech stocks are built for ‘long-term mindset’: Constellation Research founder

Constellation Research founder Ray Wang on his outlook for technology stocks like Coupang and Roblox.

Another record day on Wall Street with the Dow Jones Industrial Average marching well above the 32,000 level.

Stocks making headlines on Thursday include newly public Roblux and soon-to-public Coupang. As well as AMC and GameStop.

Follow all the market-moving events in the FOX Business Blog. Mobile users click here.

CLICK HERE TO READ MORE ON FOX BUSINESS